Immunoconjugates of the Formula (I) include a linking group for linking an antibody targeting ligand (Ab) to a drug (D). Embodiments of such immunoconjugates are useful for delivering the drug to selected cells or tissues, e.g., for the treatment of cancer.

Ab-[S-L.sup.1-L.sup.2-L.sup.3-L.sup.4-L.sup.5-L.sup.6-L.sup.7-D].sub.n   (I)

Immunoconjugates of the Formula (I) include a linking group for linking an antibody targeting ligand (Ab) to a drug (D). Embodiments of such immunoconjugates are useful for delivering the drug to selected cells or tissues, e.g., for the treatment of cancer.

Ab-[S-L.sup.1-L.sup.2-L.sup.3-L.sup.4-L.sup.5-L.sup.6-L.sup.7-D].sub.n   (I)

The invention relates to a daphnane diterpenoid resistant to a prostate cancer and a preparation method thereof. A daphnane diterpenoid compound as represented by formula (I) or formula (II) significantly inhibits the proliferation of various prostate cancer cells; the activities of some such compounds at a cellular level and an animal level are higher than that of the existing clinical targeting drug enzalutamide; and the daphnane diterpenoid compounds have strong synergistic effects when used in combination with the enzalutamide and are expected to become candidate drugs for treatment or adjuvant treatment of a castration-resistant prostate cancer.

##STR00001##

The invention relates to a daphnane diterpenoid resistant to a prostate cancer and a preparation method thereof. A daphnane diterpenoid compound as represented by formula (I) or formula (II) significantly inhibits the proliferation of various prostate cancer cells; the activities of some such compounds at a cellular level and an animal level are higher than that of the existing clinical targeting drug enzalutamide; and the daphnane diterpenoid compounds have strong synergistic effects when used in combination with the enzalutamide and are expected to become candidate drugs for treatment or adjuvant treatment of a castration-resistant prostate cancer.

##STR00001##

A conjugate comprising the following topoisomerase inhibitor derivative (A*): with a linker for connecting to a Ligand Unit, wherein the linker is attached in a cleavable manner to the amino residue. The Ligand Unit is preferably an antibody. Also provided is A* with the linking unit attached, and intermediates for their synthesis, as well as the released warhead.

##STR00001##

A conjugate comprising the following topoisomerase inhibitor derivative (A*): with a linker for connecting to a Ligand Unit, wherein the linker is attached in a cleavable manner to the amino residue. The Ligand Unit is preferably an antibody. Also provided is A* with the linking unit attached, and intermediates for their synthesis, as well as the released warhead.

##STR00001##

The present disclosure provides a novel compound of Chemical Formula 1 and an organic light emitting device including the same,

##STR00001##

X.sub.1, X.sub.2, A.sub.4, A.sub.5, Ar.sub.1, Ar.sub.2, and R.sub.1 to R.sub.4 are described herein.

The present disclosure provides a novel compound of Chemical Formula 1 and an organic light emitting device including the same,

##STR00001##

X.sub.1, X.sub.2, A.sub.4, A.sub.5, Ar.sub.1, Ar.sub.2, and R.sub.1 to R.sub.4 are described herein.

An organic electroluminescence device includes: an anode; a cathode opposite the anode; and an organic layer interposed between the anode and the cathode, in which the organic layer includes: an emitting layer; and a first electron transporting layer and a second electron transporting layer which are provided on a side of the emitting layer near the cathode. The first electron transporting layer includes a compound represented by a formula (1) below, and the second electron transporting layer includes a compound represented by a formula (2) below.

##STR00001##

An organic electroluminescence device includes: an anode; a cathode opposite the anode; and an organic layer interposed between the anode and the cathode, in which the organic layer includes: an emitting layer; and a first electron transporting layer and a second electron transporting layer which are provided on a side of the emitting layer near the cathode. The first electron transporting layer includes a compound represented by a formula (1) below, and the second electron transporting layer includes a compound represented by a formula (2) below.

##STR00001##